Tested Applications
| Positive IHC detected in | human skeletal muscle tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
55281-1-AP targets OBSCN in IHC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
| Calculated Molecular Weight | 925 kDa |
| GenBank Accession Number | NM_052843 |
| Gene Symbol | OBSCN |
| Gene ID (NCBI) | 84033 |
| RRID | AB_2881297 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q5VST9 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for OBSCN antibody 55281-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The OBSCN Polyclonal antibody (55281-1-AP) has 1 citation. It appears in the journal Cell & Bioscience (2025, IF 6.5). The citation focuses on the research field of bladder cancer, specifically studying how loss of OBSCN expression promotes bladder cancer progression and enhances the efficacy of PD-L1 inhibitors (immunotherapy), using the antibody in IHC applications.
| Species | Application | Title |
|---|---|---|
Cell Biosci Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors |



